Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials)
Related Posts
Dean PN, Brothers JA, Burns K, Edelson JB, Etheridge S, Phelan DM, Shafer K, Snyder C, Molossi S, Danielian A, Friedman EM, Hsu J, Husaini[...]
Rosovsky RP, Konstantinides SV, Moriarty JM, Dohad SY, Weinberg I, Parikh SA, Channick R, Lookstein RA. A prospective, multicenter, randomized controlled trial evaluating anticoagulation alone[...]
Heinzerling A, Harrison R, Flattery J, Fazio JC, Gandhi S, Cummings KJ. Reply to Currow et al.and to Akgün. Am J Respir Crit Care Med. 2025[...]